Learning about Prevenar 20 in the real world in Korea
Treatments studied
Part of Immune system & allergy, Infections clinical trials.
This study is for people who are already getting the Prevenar 20 vaccine (a shot that protects against pneumonia and other infections) as part of their regular care. The researchers want to see how well it works in the real world, so it's a simple way to help improve vaccines for everyone.
Summary written for real people, not researchers, by Clin2.
Who can take part
- The patient is between 6 weeks old and under 18, or 18 years or older.
- The patient's doctor has already decided to prescribe Prevenar 20 as part of their regular care.
- You (or the patient's parent/guardian) must sign a form saying you understand the study and agree to take part.
- There is no medical reason (like a severe allergy) that would make the vaccine unsafe for the patient.
- You agree to let Pfizer and its partners use your health information for the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new vaccine that protects against 21 types of bacteria that cause pneumonia and other infections. It is for healthy infants around 2 months old to see if it works as well as the current vaccine.
This early-phase study tests whether a new vaccine called V118E is safe and well-tolerated in healthy people. It is for adults who are in good health and have not recently had a pneumococcal infection.
This trial tests a new 23-valent pneumococcal vaccine to see if it safely protects healthy people against pneumonia and other infections caused by pneumococcal bacteria.
This study tests an investigational vaccine that may protect infants against infections caused by a bacteria called Streptococcus pneumoniae, which can cause pneumonia and other serious illnesses. The vaccine is given to healthy babies around 2 months old, and the study will see how well it works and how safe it is.
This study tests a new vaccine to protect infants from pneumococcal disease (a serious bacterial infection). Researchers want to see how well the vaccine works and how safe it is in healthy babies aged 2–6 months.
This trial tests a catch-up pneumococcal vaccine for children and adolescents who may have missed some doses. It aims to see how safe and effective the vaccine is in healthy kids aged 15 months to 17 years.
Hear when a new Pneumococcal Immunization trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.